Compare McKesson Corporation (MCK) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Invesco NASDAQ 100 ETF — how do they compare? McKesson Corporation trades at $828.48 (market cap $97.35B), while Invesco NASDAQ 100 ETF trades at $290.51. The key difference: McKesson Corporation pays a 0.39% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, McKesson Corporation nearer its low. Which is the better fit depends on your goals.
| MCK | QQQM | |
|---|---|---|
Market Cap | $97.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $995.69 | $307.23 |
52-Week Low | $659.01 | $228.02 |
Enterprise Value | $101.98B | — |
Dividend Yield | 0.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $831.60, down 1.16% on the day, with a bullish technical signal and positive earnings momentum after beating estimates for three consecutive quarters. The stock shows strong analyst support with an 80% buy rating and a consensus price target of $932.83, implying potential upside. Revenue growth is robust, reaching $359.05 billion in 2025, though net margins remain thin at 1.18%. Cash flow from operations improved to $6.09 billion in 2025, supporting financial stability.
The outlook for MCK is positive, driven by earnings beats, analyst optimism, and solid cash generation. Key opportunities include growth in specialty pharma and oncology services. Risks involve policy uncertainties, competitive pressures, and execution challenges. The stock's current price near key support at $829 suggests a critical level for near-term direction.
QQQM trades at $286.58 with minimal daily movement (+0.09%), reflecting a bearish technical signal amid neutral oscillators. The ETF's lower 0.15% expense ratio compared to QQQ attracts long-term growth investors, while recent Nasdaq-100 inclusion of SpaceX (1% weighting) adds diversification. Support levels cluster near $285-$283, with resistance at $288-$292.
Outlook remains tied to tech sector performance, with AI infrastructure spending by holdings like Amazon ($200B annual CapEx guidance) as a key catalyst. Risks include stretched valuations and rising AI competition. The bearish technical bias suggests near-term consolidation, but the fund's cost efficiency supports long-term growth exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
